Evaluation of Serum Scube-1 Scube-2 and Scube-3 Levels in Patients With Polikistik Over Syndrome ,

NCT03765905 | Completed DMC

• 1 other identifier: Karadeniz Technical University
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to investigate serum SCUBE-1 and SCUBE-3 levels in PCOS and non-PCOS cases compared with non-PCOS healthy controls with similar age and body mass index

Conditions

Polycystic Ovary Syndrome

Keywords

PCOS; SCUBE; Cardiovascular disease

Outcome Measures

Primary Outcomes (3)

• Serum SCUBE 1

  Serum scube1 in microgram

  01.01.2017-31.12.2017

• Serum SCUBE 2

  Serum scube2 in microgram

  01.01.2017-31.12.2017

• Serum SCUBE 3

  Serum scube3 in microgram

  01.01.2017-31.12.2017

Study Arms (2)

PCOS diagnosis area

The study group consisted of 40 reproductive age women between 18th and 35th years old women who were PCOS diagnosis (according to the 2003 Rotherdam criteria)

Diagnostic Test: study

PCOS is not diagnosed

Forty patients who did not have any complaints between the ages of 18-35 who applied to the gynecology policlinic as a control group but who had no PCOS orany other systemic problems and were similar in terms of age group and body mass index were included in the study after being approved for participation in the study

Diagnostic Test: study

Interventions

study DIAGNOSTIC_TEST

Scube-1 scube-2 scube-3

PCOS diagnosis area; PCOS is not diagnosed

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

40 women diagnosed with PCOS between the ages of 18-35

You may qualify if:

• Clinical diagnosis of PCOS
• years old

You may not qualify if:

• Endocrinopathies (including diabetes mellitus, hyperprolactinemia, Cushing's disease and congenital adrenal hyperplasia), systemic disease (eg asthma), collagen disorder, hypercholesterolemia, sickle cell anemia or neoplasm,
• Coronary artery disease , angina or myocardial infarction, or any known vascular, infectious, or inflammatory disease, including hypertension, coronary arterioscitis, and electrocardiographic changes;
• Use of any medication (e.g., insulin sensitizing drugs, oral contraceptives, antiandrogens, statins, aspirin, corticosteroids and gonadotropin releasing hormone agonists and antagonists) within the previous 3 months;
• Abnormal serum albumin concentration (normal concentration, 30-55 g / l),
• Abnormal troponin I concentration,
• Present smoker,
• Abnormal renal, hepatic and thyroid function test results;
• Refusing to participate in the work.

Sponsors & Collaborators

• Karadeniz Technical University: lead

Study Sites (1)

Karadeniz Technical University Faculty of Medicine

Trabzon, Ortahisar, 61000, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood serum

MeSH Terms

Conditions

Polycystic Ovary Syndrome; Cardiovascular Diseases

Condition Hierarchy (Ancestors)

Ovarian Cysts; Cysts; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Gonadal Disorders; Endocrine System Diseases

Study Officials

• Süleyman Güven, Prof

  Karadeniz TU Medicine Faculty

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical professor

Study Record Dates

• First Submitted: June 22, 2018
• First Posted: December 5, 2018
• Study Start: December 1, 2017
• Primary Completion: February 1, 2018
• Study Completion: February 1, 2018
• Last Updated: December 6, 2018

Record last verified: 2018-12

Locations

TU (1)